Skip to main content

Advertisement

Table 1 Patients’ characteristics

From: Immunotherapy Bridge 2018 and Melanoma Bridge 2018: meeting abstracts

  No (%)
Screened patients 150
Age, (years)
 Median 67.8
 Range 27–83
 Elderly (≥ 70) 59
Sex
 Male 105 (70)
 Female 45 (30)
ECOG PS
 0–1 114 (76)
 ≥ 2 36 (24)
Primary tumor
 NSCLC 90 (60)
 Melanoma 30 (20)
 Renal cell carcinoma 22 (14.7)
 Others 8 (5.3)
No. of metastases
 ≤ 2 47 (31.4)
 > 2 103 (68.6)
Type of anti-PD-1
 Pembrolizumab 45 (30)
 Nivolumab 105 (70)
Line of immunotherapy
 First 39 (26)
 Non-first 111 (74)
  irAEs of any grade 41 (27.3)
BMI (kg/m2)
 Median (range) 26 (16–45)
 Underweight (BMI ≤ 18.5), no (%) 5 (3.3)
 Normal weight (BMI 18.5 < BMI ≤ 24.9), no (%) 53 (35.3)
 Overweight (25 < BMI ≤ 29.9), no (%) 57 (38)
 Obese (BMI ≥ 30), no (%) 35 (23.4)